Advanced search
Publication Cover
Current Medical Research and Opinion Volume 37, 2021 - Issue 4
Submit an article Journal homepage
352
Views
0
CrossRef citations to date
0
Altmetric
Oncology

Real-world healthcare resource utilization and costs in patients with chronic lymphocytic leukemia: differences between patients treated with first-line ibrutinib or bendamustine + rituximab

Debra Irwina IBM Watson Health, Cambridge, MA, USACorrespondence[email protected]
View further author information
,
Kathleen Wilsona IBM Watson Health, Cambridge, MA, USAView further author information
,
Stephen Thompsonb Teva Pharmaceuticals Inc., Malvern, PA, USAView further author information
&
Azhar Choudhryb Teva Pharmaceuticals Inc., Malvern, PA, USAView further author information
Pages 623-628 | Received 08 Oct 2020, Accepted 28 Jan 2021, Published online: 18 Feb 2021

References

  • Society AC. Cancer facts & figures 2018. Atlanta: American Cancer Society; 2018 [cited 2019 Jul–Aug 19]. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf.
  • SEER stat fact sheets: chronic lymphocytic leukemia (CLL); 2019 [cited 2019 Jul–Aug 19]. Available from: http://seer.cancer.gov/statfacts/html/clyl.html.
  • Kabadi SM, Goyal RK, Nagar SP, et al. Treatment patterns, adverse events, and economic burden in a privately insured population of patients with chronic lymphocytic leukemia in the United States. Cancer Med. 2019;8(8):3803–3810.
  • Frey S, Blankart CR, Stargardt T. Economic burden and quality-of-life effects of chronic lymphocytic leukemia: a systematic review of the literature. Pharmacoeconomics. 2016;34(5):479–498.
  • Nabhan C, Chung J, Mato AR, et al. Comparison of costs and health care resource utilization (HRU) in chronic lymphocytic leukemia (CLL) patients treated with front-line ibrutinib or chemoimmunotherapy. Blood. 2018;132(Supplement 1):4758– 2111.
  • Hallek M. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2017;92(9):946–965.
  • IMBRUVICA. IMBRUVICA (ibrutinib) prescribing information (Revised May 2016). Sunnyvale, CA: Pharmacyclics; 2016.
  • TREANDA. TREANDA (bendamustine hydrochloride) prescribing information (Revised March 2015). North Wales, PA: Teva Pharmaceuticals USA, Inc.; 2015.
  • Zelenetz AD, Gordon LI, Wierda WG, National Comprehension Cancer Network, et al. Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. J Natl Compr Canc Netw. 2015;13(3):326–362.
  • Zelenetz AD, Gordon LI, Wierda WG, et al. Non-hodgkin's lymphomas, version 4. J Natl Compr Canc Netw. 2014;12(9):1282–1303.
  • RITUXAN. RITUXAN (rituximab) prescribing information (Revised April 2016). South San Francisco, CA: Genentech; 2016.
  • Fischer K, Cramer P, Busch R, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase ii trial of the German chronic lymphocytic leukemia study group. J Clin Oncol. 2012;30(26):3209–3216.
  • O'Brien S, Furman RR, Coutre SE, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 2014;15(1):48–58.
  • Klabunde CN, Potosky AL, Legler JM, et al. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53(12):1258–1267.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.